SCHEMBL4834401

SCHEMBL4834401

CC(C)(C)OC(=O)N1CCC2(CC1)NC(=O)N(Cc1ccc(Br)cc1)C2=O

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.48
NPC1 O15118 1/20 0.48
HTT P42858 1/20 0.48
RAB9A P51151 1/20 0.48
ALDH1A1 P00352 6/20 0.44
SMN1; SMN2 Q16637 3/20 0.44
MAPK1 P28482 1/20 0.44
TP53 P04637 1/20 0.43
HDAC1 Q13547 1/20 0.43
HDAC8 Q9BY41 1/20 0.43
HDAC6 Q9UBN7 1/20 0.43
KMT2A Q03164 1/20 0.43
TACR1 P25103 3/20 0.42
FPR2 P25090 3/20 0.42
OPRD1 P41143 1/20 0.41
OPRK1 P41145 1/20 0.41
AKR1B1 P15121 1/20 0.41
MAPT P10636 1/20 0.41
CNR1 P21554 1/20 0.40
VEGFA P15692 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3245801 0.89 KMT2A (0.56) LMNANPC1HTTRAB9AALDH1A1
SCHEMBL3392659 0.88 LMNA (0.50) LMNANPC1HTTRAB9AALDH1A1
SCHEMBL21764913 0.86 GPR119 (0.52) LMNANPC1HTTRAB9A
SCHEMBL30543496 0.86 ALDH1A1 (0.50) LMNANPC1HTTRAB9AALDH1A1
SCHEMBL21765254 0.83 NAMPT (0.43) LMNANPC1HTTRAB9AKMT2A
SCHEMBL3492232 0.82 TACR1 (0.43) SMN1; SMN2KMT2ATACR1MAPT
SCHEMBL12403872 0.82 KMT2A (0.50) LMNANPC1HTTRAB9AALDH1A1
SCHEMBL3391791 0.81 RORC (0.42) LMNANPC1HTTRAB9AKMT2A
SCHEMBL21753304 0.81 TACR1 (0.46) LMNANPC1HTTRAB9AALDH1A1
SCHEMBL30694554 0.81 TACR1 (0.45) LMNANPC1RAB9AALDH1A1SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7351713-B2 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2008-04-01 US disclosed
US-7351713-B2 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2008-04-01 US disclosed
US-7351713-B2 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2008-04-01 US disclosed
US-20050075360-A1 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity VIRO CHEM PHARMA, INC. (CA) 2005-04-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050075360-A1 Spirohydantoin compounds and methods for the modulation of chemokine receptor activity CXCR1, CXCR4, CXCR2 LMNA 4228/4885NPC1 788/4885HTT 1911/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.